Message for Participants enrolled in an ISABELA study and their caregivers in relation to COVID-19
COVID-19 is challenging for many people around the world and especially for those suffering from serious diseases like idiopathic pulmonary fibrosis. Know that Galapagos is continuously committed to advance a potential treatment in IPF and to give access to patients around the world, even in these difficult times.
We would like to inform Participants enrolled in an ISABELA study and their caregivers about the following:
- Safety of study participants is a priority. At this time, the ISABELA studies are continuing to operate, although within national/state restrictions associated with safety of the study participants and national public safety.
- Galapagos is working hard to ensure that all sites across the world are supported during these difficult times and support continuation of study participants in the ISABELA studies.
- Supportive guidance is being provided to study sites to cover all aspects of the study such as study visits, blood tests, safety assessments, study medication.
Should you have any concerns regarding the study, please contact your study site and raise any questions directly with them. Please see your Informed Consent Form for assessments and contact details.
The Galapagos Team